<DOC>
	<DOCNO>NCT00846768</DOCNO>
	<brief_summary>The primary objective trial determine effect BI 17444Cl lung function 24-hour period , inhale use Respimat inhaler patient chronic obstructive pulmonary disease . In trial four treatment 3 week duration include : 2 dosage daily administration 2 dosage administration twice daily .</brief_summary>
	<brief_title>BI 1744 CL With Respimat Once Daily Versus Twice Daily COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent ICHGCP guideline prior participation trial , include medication washout restriction 2 . All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator FEV1 &lt; 80 % predict normal postbronchodilator FEV1 / FVC &lt; 70 % Visit 1 3 . Male female patient , 40 year age old 4 . Patients must current exsmokers smoke history 10 pack year 5 . Patients must able perform technically acceptable pulmonary function test 6 . Patients must able inhale medication competent manner Respimat inhaler meter dose inhaler ( MDI ) . 1 . Patients significant disease COPD . 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; patient SGOT &gt; x2 ULN , SGPT &gt; x2 ULN , bilirubin &gt; x2 ULN creatinine &gt; x2 ULN exclude regardless clinical condition . 3 . Patients history asthma . For patient allergic rhinitis atopy , source documentation require verify patient asthma . If patient total blood eosinophil count 600/mm3 , source documentation require verify increase eosinophil count relate nonasthmatic condition . 4 . Patients respiratory infection COPD exacerbation 6 week prior Screening Visit ( Visit 1 ) baseline period . 5 . Patients follow condition : diagnosis thyrotoxicosis ; diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) 6 . Patients follow condition : history myocardial infarction within 1 year screen visit ( Visit 1 ) ; unstable lifethreatening cardiac arrhythmia ; hospitalize heart failure within past year ; know active tuberculosis ; malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) ; history lifethreatening pulmonary obstruction ; history cystic fibrosis ; clinically evident bronchiectasis ; history significant alcohol drug abuse 7 . Patients undergone thoracotomy pulmonary resection 8 . Patients treat follow concomitant medication : oral beta2adrenergics ; oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 9 . Patients regularly use daytime oxygen therapy one hour per day . 10 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) patient currently pulmonary rehabilitation program 11 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit 12 . Patients know hypersensitivity betaadrenergics drug , BAC , EDTA component Respimat inhalation solution delivery system 13 . Pregnant nursing woman 14 . Women childbearing potential use two effective method birth control ( one barrier , one nonbarrier ) . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year 15 . Patients previously randomize study currently participate another study 16 . Patients unable comply pulmonary medication restriction prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>